Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials.
2013
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and
glial cells modulating the effects of glutamatergic neurotransmission. The pharmacological manipulation of these
receptors has been postulated to be valuable in the management of some neurological disorders. Accordingly, the
targeting of mGlu 5 receptors as a therapeutic approach for Parkinson’s disease (PD) has been proposed, especially to
manage the adverse symptoms associated to chronic treatment with classical PD drugs. Thus, the specific pharmacological
blocking of mGlu 5 receptors constitutes one of the most attractive non-dopaminergic-based strategies for PD management
in general and for the L-DOPA-induced diskynesia (LID) in particular. Overall, we provide here an update of the current
state of the art of these mGlu 5 receptor-based approaches that are under clinical study as agents devoted to alleviate PD
symptoms.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
107
References
11
Citations
NaN
KQI